Verus Capital Partners LLC Invests $213,000 in DaVita Inc. (NYSE:DVA)

Verus Capital Partners LLC bought a new position in shares of DaVita Inc. (NYSE:DVA) during the third quarter, Holdings Channel.com reports. The firm bought 1,298 shares of the company’s stock, valued at approximately $213,000.

A number of other large investors also recently modified their holdings of the stock. Harvard Management Co. Inc. acquired a new position in shares of DaVita during the second quarter worth approximately $55,115,000. Lazard Asset Management LLC raised its stake in shares of DaVita by 147.3% during the first quarter. Lazard Asset Management LLC now owns 256,872 shares of the company’s stock worth $35,460,000 after buying an additional 153,008 shares during the last quarter. Andra AP fonden raised its stake in shares of DaVita by 9.0% during the second quarter. Andra AP fonden now owns 192,300 shares of the company’s stock worth $26,647,000 after buying an additional 15,800 shares during the last quarter. abrdn plc raised its stake in shares of DaVita by 1.2% during the third quarter. abrdn plc now owns 189,065 shares of the company’s stock worth $30,719,000 after buying an additional 2,180 shares during the last quarter. Finally, Jupiter Asset Management Ltd. raised its stake in shares of DaVita by 146.7% during the first quarter. Jupiter Asset Management Ltd. now owns 187,177 shares of the company’s stock worth $25,840,000 after buying an additional 111,311 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at DaVita

In other news, CEO Javier Rodriguez sold 9,881 shares of the stock in a transaction on Friday, September 13th. The shares were sold at an average price of $162.85, for a total transaction of $1,609,120.85. Following the completion of the sale, the chief executive officer now owns 887,835 shares of the company’s stock, valued at $144,583,929.75. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Javier Rodriguez sold 9,881 shares of the stock in a transaction on Friday, September 13th. The shares were sold at an average price of $162.85, for a total transaction of $1,609,120.85. Following the completion of the sale, the chief executive officer now owns 887,835 shares of the company’s stock, valued at $144,583,929.75. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Joel Ackerman sold 64,029 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the sale, the chief financial officer now directly owns 111,481 shares of the company’s stock, valued at $17,286,243.86. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 156,086 shares of company stock valued at $24,807,161 over the last quarter. Corporate insiders own 2.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on DVA shares. TD Cowen boosted their price target on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Truist Financial boosted their price target on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Barclays boosted their price target on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. UBS Group upped their target price on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Finally, Bank of America upped their target price on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $161.80.

DaVita Stock Down 0.5 %

Shares of NYSE:DVA opened at $157.23 on Thursday. DaVita Inc. has a 52 week low of $89.33 and a 52 week high of $168.50. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. The company has a market capitalization of $12.89 billion, a PE ratio of 16.96, a PEG ratio of 0.89 and a beta of 0.89. The company has a 50 day moving average price of $157.46 and a two-hundred day moving average price of $147.30.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. During the same period in the prior year, the company earned $2.85 EPS. The firm’s revenue was up 4.6% on a year-over-year basis. Analysts forecast that DaVita Inc. will post 9.71 earnings per share for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.